Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 3, 1999, Pages 187-192

  Koshkina, Nadezhda V ^a   Waldrep, J Clifford ^a   Seryshev, Alexander ^a   Knight, Vernon ^a   Gilbert, Brian E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aerosol; Camptothecin; Cancer; Liposome; Mice; Pharmacokinetics

Indexed keywords

ALKALOID; DILAUROYLPHOSPHATIDYLCHOLINE; PLANT EXTRACT; RUBITECAN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; COLON CANCER; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; INHALATIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

AEROSOLS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG CARRIERS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; PHOSPHATIDYLCHOLINES;

EID: 0032807781     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050966     Document Type: Article

References (23)

1. 1. Ahmed EA, Jacob S, Giovanella BC, Kozielsky AJ, Stehlin JS, Liehr JG (1996) Influence of route of administration on [3H]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies. Cancer Chemother Pharmacol 39: 122
2. 2. Andersen AA (1958) New sampler for the collection, sizing and enumeration of viable airborne particles. J Bacteriol 76: 471
3. 3. Burke TG, Gao X (1994) Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J Pharm Sci 83: 967
4. 4. Burke TG, Mi Z (1993) Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212: 285
5. 5. Burke TG, Mi Z (1994) The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37: 40
6. 6. Burke TG, Staubus AE, Mishra AK (1992) Liposomal stabilization of camptothecin's lactone ring. J Am Chem Soc 114: 8318
7. 7. Burke TG, Mishra AK, Wani MC, Wall ME (1993) Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 32: 5352
8. 8. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF (1991) Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51: 6039
9. 9. Daoud SS, Fetouh MI, Giovanella BC (1995) Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts. Anticancer Drugs 6: 83
10. 10. Fairchild GA (1972) Measurement of respiratory volume for virus retention studies in mice. Appl Microbiol 24: 812
11. 11. Giovanella BC, Hinz HR, Kozielsky AJ, Stehlin JS, Silber JR, Potmesil M (1991) Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51: 3052
12. 12. Giovanella BP, Natelson E, Harris N, Vardeman D, Stehlin JS (1996) Protocols for the treatment of human tumor xenografts with camptothecins. Ann NY Acad Sci 803: 181
13. 13. Hendrics CB, Rowinsky EK, Grochow LB, Donchower RC, Kaufmann SH (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F104864), a new camptothecin analogue. Cancer Res 52: 2268
14. 14. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomeraze I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49: 1465
15. 15. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE (1999) Anti-cancer effect of 9-nitro camptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 44: 177
16. 16. Koshkina NV, Waldrep JC, Gilbert BE, Giovanella BC, Knight V (1998) Anticancer effect of 9-nitrocamptothecin aerosol delivery on human cancer xenograft models. Proc. of the 89th annual meeting of the Am Assoc Cancer Research 39: Abstract #1902, Cadmus Journal Services, Linthicum, Md., p 278
17. 17. Natelson EA, Giovanella BC, Vershraegen CF, Fehir KM, De Ipolyi PD, Harris N, Stehlin JS (1996) Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 803: 224
18. 18. Pantazis P (1995) Preclinical studies of water-insoluble CPT congeners: cytotoxicity, development of resistance and combination treatment. Clin Cancer Res 1: 1235
19. 19. Pantazis P, Kozielsky AJ, Vardeman DM, Petry ER, Giovanella BC (1993) Efficacy of CPT congeners in the treatment of human breast carcinoma xenografts. Oncol Res 5: 273
20. 20. Patton JC (1996) Mechanisms of macromolecule absorption by the lungs. Adv Drug Delivery Rev 19: 3
21. 21. Phalen RF (1984) Inhalation studies; foundations and techniques. CRC Press, Boca Raton p 222
22. 22. Sugarman SM, Zou Y, Wasan K, Kumi R, Reddy S, Perez-Soler R (1996) Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. Cancer Chemother Pharmacol 37: 531
23. 23. Verschraegen CF, Natelson EA, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Ende K, Stehlin JS (1998) A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 9: 36